A Polycomb-mir200 loop regulates clinical outcome in bladder cancer

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Bladder cancer (BC) is a prevalent malignancy with unmet needs in prognostic biomarkers.
• MicroRNAs (miRNAs), including the miR-200 family, are implicated in cancer progression by regulating epithelial-to-mesenchymal transition (EMT).
• The role and expression of the miR-200 family in BC remain largely unexplored.

Purpose of the Study:

• To investigate the expression patterns and functional significance of the miR-200 family in bladder cancer.
• To explore the relationship between miR-200 family expression, tumor grade/stage, and patient outcomes.
• To elucidate the regulatory mechanisms involving the miR-200 family, EMT factors, and Polycomb Repression Complex (PRC) members in BC.

Main Methods:

• Analysis of miR-200 family expression in BC versus normal bladder tissues.
• Correlation of miRNA expression with tumor grade, stage, and clinical outcomes.
• Investigation of miR-200 family's regulatory roles on EMT-promoting transcription factors (ZEB1, ZEB2) and BMI1.
• Assessment of EZH2 and BMI1 influence on miR-200 expression.
• Evaluation of EZH2 inhibition effects on miR-200 expression in BC cell lines.

Main Results:

• miR-200 family expression is altered in BC, with reduced promoter methylation and increased expression in early stages, but decreased in high-grade/stage tumors.
• Down-regulation of miR-200 family correlates with poor clinical outcomes in BC patients.
• miR-200 family targets ZEB1/ZEB2 in muscle-invasive BC (MIBC) and BMI1 in non-muscle-invasive BC (NMIBC).
• EZH2 and BMI1 expression inversely correlates with miR-200 family expression, suggesting PRC-mediated repression.
• Pharmacological inhibition of EZH2 increases miR-200 expression in BC cell lines.

Conclusions:

• The miR-200 family exhibits distinct roles in different stages of BC progression.
• Dysregulation of the miR-200 family, influenced by PRC members like EZH2 and BMI1, contributes to BC invasiveness.
• Targeting EZH2 may represent a novel therapeutic strategy to restore miR-200 expression and combat BC.